Effect of JAK1/2 inhibition on High-Output Heart Failure Associated With Myeloproliferative Disease

• Yuki Fujii, MD,
• Makoto Takei, MD,
• Risa Hayashi, MD,
• Ryuichiro Yagi, MD,
• Megumi Kawano, MD,
• Ayaka Endo, MD,
• Kenji Suzuki, MD,
• Naoki Hirata, MD,
• Tasuku Hasegawa, MD,
• Toshiyuki Takahashi, MD

Affiliations

Yuki Fujii, MD

Department of Cardiology, Saiseikai Central Hospital, Tokyo, Japan

Makoto Takei, MD

Address for correspondence: Dr. Makoto Takei, Department of Cardiology, Saiseikai Central Hospital, Mita 1-4-17, Minato-ku, Tokyo 108-0073, Japan.; Department of Cardiology, Saiseikai Central Hospital, Tokyo, Japan

Risa Hayashi, MD

Department of Cardiology, Saiseikai Central Hospital, Tokyo, Japan

Ryuichiro Yagi, MD

Department of Cardiology, Saiseikai Central Hospital, Tokyo, Japan

Megumi Kawano, MD

Department of Cardiology, Saiseikai Central Hospital, Tokyo, Japan

Ayaka Endo, MD

Department of Cardiology, Saiseikai Central Hospital, Tokyo, Japan

Kenji Suzuki, MD

Department of Cardiology, Saiseikai Central Hospital, Tokyo, Japan

Naoki Hirata, MD

Department of Cardiology, Saiseikai Central Hospital, Tokyo, Japan

Tasuku Hasegawa, MD

Department of Cardiology, Saiseikai Central Hospital, Tokyo, Japan

Toshiyuki Takahashi, MD

Department of Cardiology, Saiseikai Central Hospital, Tokyo, Japan